In a patient with tenosynovitis caused by oxacillin‑sensitive Staphylococcus aureus, can I prescribe oral cephalexin (Keflex) and what dose and duration are appropriate?

Treatment of Oxacillin-Sensitive Staphylococcus Tenosynovitis with Oral Cephalexin

Yes, oral cephalexin (Keflex) is an appropriate treatment for oxacillin-sensitive Staphylococcus aureus tenosynovitis, dosed at 500 mg four times daily for 7-14 days, with consideration for longer duration (up to 21 days) depending on clinical response and severity.

Rationale for Cephalexin Use

Cephalexin is explicitly recommended by the Infectious Diseases Society of America (IDSA) for methicillin-sensitive Staphylococcus aureus (MSSA) skin and soft tissue infections 1. The guidelines list cephalexin as an appropriate oral agent for MSSA infections, noting it is suitable "for penicillin-allergic patients except those with immediate hypersensitivity reactions" and highlighting "the availability of a suspension and requirement for less frequent dosing" 1.

Dosing Recommendations

Standard Adult Dosing

• 500 mg orally four times daily (every 6 hours) is the standard dose for MSSA soft tissue infections 1
• The FDA label confirms adult dosing ranges from 1-4 grams daily in divided doses, with 500 mg every 6 hours being standard for more severe infections 2
• For infections caused by less susceptible organisms or more severe presentations, higher doses may be needed 2

Alternative Dosing Considerations

• Twice-daily dosing (500 mg BID) has been studied and shown equal efficacy to four-times-daily dosing in some skin infections 3, 4, though this was primarily for impetigo and less severe infections
• High-dose cephalexin (1000 mg four times daily) showed lower treatment failure rates (3.2% vs 12.9%) in a pilot trial for cellulitis, though with more minor adverse effects 5
• Given tenosynovitis is a deeper soft tissue infection than simple cellulitis, I recommend the standard 500 mg QID dosing rather than twice-daily regimens 1

Duration of Therapy

Recommended Duration

• Minimum 7-14 days for uncomplicated soft tissue infections 2, 6
• Consider 14-21 days for tenosynovitis given it involves deeper structures (tendon sheath) similar to osteoarticular infections 7
• The IDSA guidelines note that for β-hemolytic streptococcal infections, at least 10 days is required, and similar duration should be considered for staphylococcal deep soft tissue infections 1

Clinical Monitoring

• Assess clinical response at 72 hours: Look for reduction in erythema, swelling, tenderness, and absence of fever 6, 8
• Treatment failure criteria include: fever persistence, increase in erythema (>25%), swelling or tenderness at days 3-4, or no decrease in these parameters by days 8-10 8
• If no improvement by 72 hours, consider imaging to exclude abscess, switching to IV therapy, or broadening coverage for possible MRSA 1

Important Clinical Caveats

When Cephalexin May Not Be Appropriate

• Severe systemic toxicity (SIRS criteria: fever >38°C or <36°C, tachycardia >90, tachypnea >24, WBC >12,000 or <4,000) warrants IV therapy initially 1
• Purulent drainage or abscess formation requires incision and drainage; antibiotics alone are insufficient 1
• Failed outpatient therapy or immunocompromised status may require IV vancomycin or other agents 1

Surgical Considerations

• Tenosynovitis often requires surgical drainage or irrigation in addition to antibiotics, particularly if there is purulent material or lack of response to initial therapy 1
• Prompt surgical consultation is recommended for aggressive infections with systemic toxicity 1

Alternative Oral Agents for MSSA

If cephalexin is not tolerated or contraindicated:

• Dicloxacillin 500 mg QID is the oral agent of choice for MSSA in adults per IDSA guidelines 1
• Clindamycin 300-450 mg QID is an alternative, though bacteriostatic with potential for resistance 1
• Trimethoprim-sulfamethoxazole has limited efficacy data and should not be first-line 1

Pitfalls to Avoid

• Do not use cephalexin for MRSA: It has no activity against methicillin-resistant strains 1
• Ensure adequate dosing: Underdosing (e.g., 250 mg QID) may be insufficient for deeper infections 2
• Do not stop antibiotics prematurely: Tenosynovitis requires longer courses than superficial cellulitis to prevent recurrence 7
• Monitor for treatment failure: Up to 20% of cellulitis cases fail initial therapy; early reassessment is critical 5